Diabetes care
Generalizability of Progression Risk in the TN-10 Trial to a European Population With or Without a First-Degree Relative With Type 1 Diabetes.
Melanie Koeger, Christiane Winkler, Sandra Hummel, Andreas Weiss, Thibaut Koutangni, Mark Yates, Mireille Bonnemaire, Oliver Guenther, Julia Zaccai, Anette-Gabriele Ziegler
Published: 202510.2337/dc25-1021
Abstract
OBJECTIVE: In the TrialNet 10 Anti-CD3 Prevention (TN-10) trial, teplizumab delayed onset of stage 3 type 1 diabetes in U.S. and Canadian individuals with stage 2 disease who had a relative with type 1 diabetes. Here, the generalizability of the popu…
Preview only. Read the full abstract at the source